Summit Therapeutics Share Discussion Threads

[algernon2] 07/11/2017 13:57

[...]

Thanks Hugus: Worth watching not only for the news but to see what appears to be Glyn's giant new glasses and to see from the bookcase behind him what he has been reading.Also the incessant pings as he gets an email and tries not to let his eyes or attention wander from the interview.

Overall very encouraging.

[hugus maximus] 07/11/2017 13:37

Glyn on ProInvestor at lunchtime :
www.proactiveinvestors.co.uk/companies/stocktube/8337/summit-therapeutics-in-a-great-position-nearing-the-business-end-of-its-development-8337.html

Edit: At the head of the address add the following with lowercase letters:-


ADVFN seems to censor more and parts of link addresses ... which is unhelpful.

[wildbunch] 07/11/2017 11:03

Like this WT deal. If Summit gets taken out LSB (lock stock and barrel) then there will be no argument about how much of the exit price will be c diff related. The % of revenue is much cleaner. Big question is whether this is just far sighted strategic thinking or something in the near term. Current share price could make Summit appear an attractive proposition and recent share options granted at exercise price sub £2 would be a nice little earner if taken out at say £10ish.

[luminoso] 06/11/2017 20:04

Agree waterloo. I can't help feeling that Sarepta will be looking to take more of EZT in due course, if not all of it, if they want to be the leaders in DMD. After all it might just work !
It will be interesting to see if they try and raise more money on the back of this surge in their share price I think I would be buying more Summit, if that happens.
Meanwhile, the nasdaq has cheered up a bit in the last hour.

[waterloo01] 06/11/2017 16:26

Undervalued here at £95m so happy to hold/add around these levels.

Hopefully F3 will show some efficiency, but if F6 (only 10 kids) shows significant improvements over and above in MRI and some of the other measures, it will 'prove' up the approach of Utrophin upregulation, as if F3 works but F6 works even better it gives some confidence that they have an active drug that works better the more it's bio-available.

I'd also say the 2 big bits of news (SRPT buying in and Barda grant) both came out the blue, so who knows but I'm sure they are fairly focused on it as there is a great deal riding on the results.

I also note SRPT have got approvals to eat their own lunch with some gene editing trials (phase 1/2a) including use in babies. It might or might not be one of the many approaches that work, but the trials will be long running (many years) and long after we will know if we have a DMD drug approved or not

[hugus maximus] 06/11/2017 16:08

Agree Waterloo ... wondering if the NASDAQ saw Sarpeta shareholders move across to Summit earlier in the year, and now after much hot air in the Sarapeta camp, they're jumping back again? I'm still not convinced by Exondys 51 which is what Sarepta needs to achieve proof of concept with by 2019 ... and that is still what underpins the company.

If Summit pip them to the post with a seriously proven "proof of concept", backed up by their much more forensic trials, the market will turn back to Summit next year.

Meanwhile, as you suggest, I also think folk in the USA don't understand the true value of what's going on in the background with Summit's C Diff drug ... perhaps todays RNS is a clearing of the air with the Welcome trust in advance of a larger third party proposition? The press is full of support for the desperate necessity in finding a new generation of anti-biotics and RDZ is a clear winner ... all they need is a 3rd party with a realistic pricing strategy versus decent royalty. (all IMHO)

[waterloo01] 06/11/2017 15:36

Don't think they get it. We now own a lot more of RDZ with any contribution coming out of SUMM's RDZ earnings, rather than upfront and clears the way for a deal IMO.

[football] 06/11/2017 15:33

Well it seems the NASDAQ doesn't think a lot of it

[luminoso] 06/11/2017 14:06

Will be interesting to see how nasdaq reacts in a few minutes.

[chrisatrdg] 06/11/2017 13:56

Following on from waterloo01 'it must surely be clearing the way for them to do ANO deal/sale'.

There must be further funds coming from a C-Diff financing deal which must be dependant on issuing additional equity within the company in exchange for full financing to see C-Diff through to market hence Wellcome Trust willingness to drop their 20% in exchange for income based on future success for C-Diff.

Watch this space.

[tightfist] 06/11/2017 12:39

Looks like it's clearing the decks in readiness for something value-adding, or at least more flexibility to seal a deal.

[phowdo] 06/11/2017 12:25

Or for someone to buy them outright...

[waterloo01] 06/11/2017 12:06

Now that's interesting. So their 20% ownership is changed for a % share of sales. Does this clear the way for them to do ANO deal/sale?

[chrisatrdg] 03/11/2017 16:42

At $53.61 Serepta currently are at a 52 wk high maybe people are bailing out of Summit & Buying into Serepta who have their feet in several camps & could Buy Summit outright with no real problem.

In addition all the news postings on Serepta NASDAQ 'board' are all very positive.

[chrisatrdg] 03/11/2017 16:29

Hi H.M. I think it is all fantasy & note that the NASDAQ is matching AIM at $9.18 & each is pulling the other down & do not see share price has bottomed out yet clearly someone/people Stateside are not happy with Summit.As has been said before current AIM Market Capitalisation is £102.41m which must value C-Diff at that let alone without DMD.

At current share price both UK & USA must be tempting for a Buy Out - is that what the current share price movements are about - just speculating.

[hugus maximus] 03/11/2017 14:03

luminoso ... Sarepta up again today because the FDA has signed off on their IND for gene therapy GALGT2 (very early days but another potential treatment for DMD)

I wonder how things will turn out with their old friend Exondys 51? The truth may out with more rigorous trial results TBA in 2019? They've managed some amazing navigation through such a potential mess. By the time they have to deal with anything problematic with Exondys 51, last year's FDA decision will be old news and they'll be riding off into the sunset with Summit's DMD drug ;-/

© A Fantasy Film Production (any comparison with the eventual outcome may be coincidental)

[luminoso] 03/11/2017 13:48

Sarepta seem more popular in the DMD space at the moment and have the momentum we lack.

[waterloo01] 03/11/2017 13:11

Senitment dear boy, sentiment. We could go up 30% and still be below the recent discounted placing. A 50% rise would only take us to where we were before it.

Time to add IMO.

[chrisatrdg] 03/11/2017 13:03

Well it is now past 12.00 & no RNS which suggests that the science remains strong & we just have to put the share price reduction down to people stateside wanting to Sell Summit & Buy into another share.Hopefully the blip will end soon & we now wait to next year.Regards all.

[waterloo01] 03/11/2017 09:35

Most on here know my views of late, however I do feel this sell off is overdone and have added again on the dips. As far as I know there isn't any 'bad' news out there but a seller seems active in the US. This can quickly change as it's driven by sentiment.

The research article posted a few days ago is new and does support Utrophin as an approach. I've suggested they might like to tweet it at the very least.

The current market cap is just under £100m, which is deserved on RDZ alone, especially given the $60m+ Barda grant only a few weeks ago.

[hugus maximus] 03/11/2017 09:27

Whoops ... been away from my post. What on earth is this all about? I see the NASDAQ rallied UP (!!) to £1.43 ($9.4) last night. Without any reported change in the science or basics in the company, this is odd behaviour. Surely just a small pharma with a P2 C Diff cure preparing P3 is worth more than this? (i.e. aside from any DMD potential)

Doesn't this make things frighteningly ripe for an aggressive takeover at this SP, whilst the company seems so ripe for success?

[waterloo01] 03/11/2017 07:53

Some relevance re RDZ and again suggest that 'poop' treatment carries other significant risk in messing with the biome and introducing another persons might have side effects IMO.

[algernon2] 02/11/2017 22:15

"Roll up Roll up and .. Spin the wheel Where it will stop nobody knows!"

We are back to approx 7.5pence per share(old value).Outrageous. I will be buying some more soon but amazed at the price.Where's Freedosh when we need some moral support/encouragement.

[luminoso] 02/11/2017 22:14

I think 8.8 on nasdaq was probably the bottom, Chris. I certainly hope so anyway.